<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of stem cells</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of stem cells</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of stem cells</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Marc HGP Raaijmakers, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nelson J Chao, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer S Tirnauer, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H541321347"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Stem cells are cells that are capable of self-renewal and differentiation. Embryonic stem (ES) cells can form the entire human body. Somatic (adult) stem cells can form an entire organ or tissue; they were first identified in the hematopoietic system and are believed to be present in many other tissues. </p><p>Stem cell-based therapies have altered the care of individuals with hematologic, oncologic, dermatologic, ophthalmologic, and orthopedic conditions.</p><p>This topic reviews stem cell biology, clinical and research applications, and ethical considerations. Separate topics discuss the biology and clinical use of hematopoietic stem cells. (See  <a class="medical medical_review" href="/d/html/3536.html" rel="external">"Overview of hematopoietic stem cells"</a> and  <a class="medical medical_review" href="/d/html/3537.html" rel="external">"Hematopoietic cell transplantation (HCT): Sources of hematopoietic stem/progenitor cells"</a>.) </p><p class="headingAnchor" id="H1224104671"><span class="h1">STEM CELL BIOLOGY</span></p><p class="headingAnchor" id="H3982123"><span class="h2">What defines a stem cell?</span><span class="headingEndMark"> — </span>All stem cells share two cardinal features: they are capable of self-renewal and they can differentiate. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Self-renewal </strong>– Self-renewal is the ability of a cell to proliferate and produce daughter stem cells that retain stem cell potential, without the loss of differentiation potential and without undergoing senescence (biologic aging). In principle, stem cell renewal is indefinite. Other types of cells that are not stem cells may be able to self-renew for a limited number of cell divisions. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiation</strong> – Differentiation is the ability of a cell to develop into another cell type with a dedicated, specific function that cannot be executed in the nondifferentiated state. Differentiation capacity is not limited to stem cells, but the combination of self-renewal and differentiation potential is unique to stem cells.</p><p></p><p>A variety of cell types are not stem cells. Progenitor or precursor cells are distinct in that they are able to proliferate and differentiate, contributing to tissue regeneration, but they lack the potential for self-renewal. Progenitor cells arise from stem cells and typically have a limited lifespan and a limited number of possible cell divisions. </p><p class="headingAnchor" id="H3328767708"><span class="h2">Symmetric versus asymmetric stem cell division</span><span class="headingEndMark"> — </span>Cell division occurs through the process of DNA replication and mitosis. (See  <a class="medical medical_review" href="/d/html/129424.html" rel="external">"Basic genetics concepts: Chromosomes and cell division", section on 'Mitosis'</a>.)</p><p>Stem cells can divide symmetrically or asymmetrically  (<a class="graphic graphic_figure graphicRef54474" href="/d/graphic/54474.html" rel="external">figure 1</a>); the daughter cells may be stem cells, more differentiated cells, or one of each [<a href="#rid1">1,2</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symmetric stem cell division</strong> – Produces two daughter cells that are either both stem cells or both differentiated cells. Symmetric stem cell division that produces two daughter stem cells will increase the stem cell pool. Symmetric stem cell division that produces two differentiated daughter cells will deplete the stem cell pool.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymmetric stem cell division</strong> – Produces one replacement stem cell and one cell that is more differentiated.</p><p></p><p class="headingAnchor" id="H685335887"><span class="h2">Degrees of stem cell potency</span><span class="headingEndMark"> — </span>The potency of a stem cell is defined by the types of differentiated cells (or other stem cells) it can produce  (<a class="graphic graphic_table graphicRef78504" href="/d/graphic/78504.html" rel="external">table 1</a>). Classically, the potency of cells has been thought to be determined by the stage of embryonic development at which they are created. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Totipotent</strong> – Totipotent stem cells have the capability to produce all cell types of the developing organism, including both embryonic and extraembryonic (eg, placental) tissues. Cells that arise from the first few cell divisions following fertilization of the egg are generally the only cells thought to have totipotency. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pluripotent</strong> – Pluripotent stem cells can only make cells of the embryo proper, but they can make all cells of the embryo including germ cells and cells from any of the germ layers. Therefore, they can make any cell of the body.</p><p></p><p class="bulletIndent1">Pluripotency is thought to be limited to stem cells derived from either the inner cell mass of the blastocyst (a preimplantation stage of development occurring approximately 7 to 10 days after fertilization) or nascent germ cells in the embryo. Pluripotent stem cells are created from divisions of totipotent stem cells.</p><p></p><p class="bulletIndent1">Cells cultured and cell lines established from these structures are called embryonic stem (ES) cells and embryonic germ cells, respectively. Pluripotent cells can be created in the laboratory from other cell types as well. (See <a class="local">'Induced pluripotent stem (iPS) cells'</a> below.)</p><p></p><p>Once the primitive streak forms in an embryo (day 10 to 14 postfertilization), most stem cells in that embryo are thought to be restricted to multipotency or unipotency. These have often been called somatic or "adult" stem cells. (See <a class="local">'Somatic stem cells'</a> below.) </p><p>Stem cells derived from umbilical cord blood are sometimes mistakenly considered equivalent to ES cells in the lay press, but they are actually multipotent somatic stem cells; they are also called hematopoietic stem cells because they give rise to the hematopoietic system.</p><p>Adult (somatic) stem cells can be multipotent or unipotent.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multipotent </strong>– Multipotent stem cells can produce different types of cells within a given germ layer. For example, multipotent stem cells from a mesodermal tissue like the blood (hematopoietic stem cells) can make all the blood cell types, including white blood cells (WBCs), red blood cells (RBCs), and platelets, but they cannot make cells of a different germ layer such as neural cells (ectoderm) or liver cells (endoderm).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Unipotent </strong>– Unipotent stem cells make a single cell type. An example is a stem cell in the skin that can contribute to maintenance of the epidermis [<a href="#rid3">3</a>].</p><p></p><p class="headingAnchor" id="H2981185684"><span class="h2">Cancer stem cells</span><span class="headingEndMark"> — </span>A model that is gaining support in animal models hypothesizes that cancers, including solid tumors and hematologic malignancies, contain a definable population of malignant cells that can be demonstrated to have the two cardinal features of stem cells, self-renewal and differentiation capacity. (See <a class="local">'What defines a stem cell?'</a> above.)</p><p>These cells, like stem cells in nonmalignant tissues, could continually replace more mature cells of the tumor that have a limited lifespan. They are therefore hypothesized to be the cells that enable persistence and perhaps metastasis of tumors.</p><p>Experimental support for the cancer stem cell hypothesis has been generated in immunodeficient mice engrafted with human cancer stem cells [<a href="#rid4">4,5</a>]. In these animals, a subset of tumor cells is capable of engrafting the tumor, while other subsets cannot. Further, the tumor-initiating subset can be sequentially transplanted to initiate new tumors and can yield the full diversity of cells observed in the original malignancy, thereby fulfilling the experimental definition of stem cells. </p><p>A subpopulation of cancer cells that behave as cancer stem cells has been demonstrated in several tumor types [<a href="#rid4">4-10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Acute myelogenous leukemia</p><p class="bulletIndent1"><span class="glyph">●</span>Breast cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Colon cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Ovarian cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Pancreatic cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Head and neck cancer</p><p class="bulletIndent1"><span class="glyph">●</span>Malignant glioma</p><p></p><p>Whether all tumors have a subset of cancer stem cells is controversial. Further, much of the definition of whether cancer stem cells exist depends on engraftment in the immunodeficient mice, which is not necessarily a good surrogate for behavior in the person from whom the cancer cells were derived. However, the model is beginning to impact development and testing of therapies in oncology. (See <a class="local">'Research applications'</a> below.)</p><p class="headingAnchor" id="H3982130"><span class="h1">SOURCES OF STEM CELLS FOR CLINICAL USE OR RESEARCH</span><span class="headingEndMark"> — </span>Stem cells can be derived from human embryos or somatic tissues, or they can be created in the laboratory by inducing greater potency in an already differentiated somatic cell, sometimes referred to as "de-differentiation."</p><p class="headingAnchor" id="H10490932"><span class="h2">Embryonic stem (ES) cells</span><span class="headingEndMark"> — </span>ES cells are typically derived from a preimplantation blastocyst (7 to 10 days postfertilization). They have the capacity to become an embryo.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use</strong> – Preimplantation genetic testing is done by removing a single ES cell from a developing embryo produced by in vitro fertilization (IVF). The cell can be tested for genetic abnormalities. If the remaining embryo (minus the cell that was removed) is transferred to the uterus and implants, it can develop normally into a fetus. Testing of ES cells from different embryos can allow selection of those embryos that lack a specific genetic abnormality for transfer. (See  <a class="medical medical_review" href="/d/html/6783.html" rel="external">"Preimplantation genetic testing"</a>.) </p><p></p><p class="bulletIndent1">Therapeutic uses of ES cells are discussed below. (See <a class="local">'Embryonic stem (ES) cell-based replacement therapy (investigational)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Research use</strong> – ES cells are a valuable source of cells to study developmental processes and related disorders because they have pluripotent capacity, with the versatility to give rise to virtually any cell type or tissue [<a href="#rid11">11</a>]. The most frequent techniques used to derive ES cells for research is to disrupt the blastocyst from which the cells are derived. </p><p></p><p class="bulletIndent1">Ethical considerations have prompted research into other stem cell sources. (See <a class="local">'Ethical considerations'</a> below.)</p><p></p><p>Stem cells obtained from umbilical cord blood are not ES cells; they are a type of multipotent somatic stem cell. (See <a class="local">'Degrees of stem cell potency'</a> above.)</p><p class="headingAnchor" id="H10490925"><span class="h2">Somatic stem cells</span><span class="headingEndMark"> — </span>Somatic stem cells (sometimes referred to as tissue-specific stem cells or adult stem cells) are thought to be present in most tissues and to persist throughout life  (<a class="graphic graphic_figure graphicRef67256" href="/d/graphic/67256.html" rel="external">figure 2</a>). One of the few organs thought to lack stem cells is the pancreas, although failure to demonstrate pancreatic stem cells may be the result of technical limitations rather than their true absence. </p><p>Tissue-specific stem cells are thought to provide the basis for tissue maintenance and response to injury. It is possible that stem cells are a durable source of replacement cells in some tissues but not in others.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissues with high cell turnover</strong> – Stem cells are especially important for tissues where there is high cell turnover, such as the blood, skin, and intestine. Stem cells in these tissues have been clearly defined experimentally [<a href="#rid12">12-14</a>]. Hematopoietic stem cells are thought to account for the complete restoration of blood cell production and bone marrow regeneration following extensive cell damage to bone marrow with cancer chemotherapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissues with less turnover</strong> – There is also evidence for a possible stem cell population for some tissues where the rate of cell turnover is lower, such as muscle, brain, and kidney [<a href="#rid15">15-18</a>]. </p><p></p><p class="bulletIndent1">For some tissues, including the islet cells of the pancreas, it is not clear whether adult stem cells exist [<a href="#rid19">19,20</a>]. A report suggesting the possibility of lung stem cells was retracted [<a href="#rid21">21,22</a>].</p><p></p><p class="bulletIndent1">In tissues lacking stem cells, proliferation of more mature cells, including progenitor cells, precursor cells, or terminally differentiated cells, may be the basis for replacement when needed. The main implication is that mature cells are thought to have a limited number of cell divisions, as opposed to stem cells, which can self-renew indefinitely. (See <a class="local">'What defines a stem cell?'</a> above.)</p><p></p><p>When tissue injury is extensive, a tissue that depends upon residual mature cells to replace the injured cells may be more limited in its regenerative capacity than tissues that can rely on resident stem cells. This is one hypothesis for the failure of pancreatic islet damage to be repaired in type 1 diabetes mellitus. (See  <a class="medical medical_review" href="/d/html/1800.html" rel="external">"Pathogenesis of type 1 diabetes mellitus"</a>.)</p><p class="headingAnchor" id="H3982137"><span class="h2">Induced pluripotent stem (iPS) cells</span><span class="headingEndMark"> — </span>The idea that stem cell potential mirrors the stage of development at which the cells were harvested, and that potency is progressively reduced during development, dramatically changed in 2006. </p><p>In a remarkable set of experiments, genes encoding transcription factors expressed in pluripotent ES cells were introduced into mature cells [<a href="#rid23">23</a>]. This was done in a way that the genes would be "ectopically" expressed rather than suppressed by the normal genetic machinery. A small number of these mature cells reverted back (de-differentiated) into a highly immature state resembling an ES cell. </p><p>This process, referred to as reprogramming, induces a pluripotent state in a previously differentiated cell type  (<a class="graphic graphic_figure graphicRef81456" href="/d/graphic/81456.html" rel="external">figure 3</a>). These cells are therefore called iPS cells. </p><p>The ability to induce pluripotency has resulted in new insights and implications for therapy and research.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Insight</strong> – The ability to create an iPS cell from a differentiated cell indicates that a cell's state of differentiation, and thus its function, can be manipulated. Cells have a plasticity that is far greater than previously recognized. As an example, a keratinocyte derived from the skin can be induced to become a pluripotent stem cell, essentially rewinding the cell's history to revert to an embryonic-like state.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Therapeutic implications</strong> – A cell taken from an individual can be induced to be capable of forming any other cell type in that individual's body. As an example, a skin or blood sample obtained from a patient with a degenerative brain disorder could in principle be converted into a pluripotent stem cell that in turn could become a source for generating the neural cells affected by the disease. This would bypass the transplantation barrier by which neural cells from another individual can induce an immune response requiring potent immunosuppression. Creation of iPS cells to treat disease is at an early investigational stage and is not in clinical use. (See <a class="local">'Induced pluripotent stem (iPS) cell-based therapies (investigational)'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Research implications</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Disease models</strong> – iPS cells allow investigators to generate disease models in the laboratory using easily obtained human cells for disorders where obtaining primary tissue, or developing reliable animal models, has been difficult. This includes heritable neurologic disorders, in which all of the body's cells contain the pathogenic genetic variants and for which neural tissue is challenging to obtain.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Personalized medicine</strong> – An iPS from a given individual represents a highly personalized source of cells. While technologies to generate iPS involve genetic manipulations, it is anticipated that other methods will be developed to generate iPS cells that are genetically identical to the individual and have less risk of genetic abnormalities. Such cells could be used to assess "personalized" drug therapies and may represent a source of immunologically identical cells for drug testing and/or transplantation.</p><p></p><p class="bulletIndent2">Further modifications of the iPS methodology are under active development. As an example, treatment of somatic cells with a cocktail of small molecule compounds was shown to alter gene expression in a similar pattern to that induced by ectopic expression of embryonic genes [<a href="#rid24">24</a>]. These advances raise the prospect of future use of iPS for therapeutic purposes. (See <a class="local">'Induced pluripotent stem (iPS) cell-based therapies (investigational)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Epigenetic regulation</strong> – As cells in the body differentiate, the genes that give them stem cell features are not removed; they are merely repressed by the genetic machinery, often via epigenetic mechanisms. Epigenetic changes involve modifications to the DNA that do not change the fundamental nucleic acid sequence. Research on altering stem cell potency may shed light on epigenetic regulation. (See  <a class="medical medical_review" href="/d/html/14601.html" rel="external">"Principles of epigenetics", section on 'Overview of regulation'</a>.) </p><p></p><p class="headingAnchor" id="H3982144"><span class="h1">CLINICAL APPLICATIONS</span><span class="headingEndMark"> — </span>The evolving role of stem cells and range of possible applications in clinical medicine is developing along several lines  (<a class="graphic graphic_table graphicRef69800" href="/d/graphic/69800.html" rel="external">table 2</a>). </p><p>Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Stem cells as therapy (to replace endogenous cells that have been damaged or destroyed, or to modify the behavior of other cells). (See <a class="local">'Stem cells as cell replacement therapy'</a> below and <a class="local">'Use of non-engrafting mesenchymal stem cells to modify disease course'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stem cells as targets of drug therapy. (See <a class="local">'Endogenous stem cells as targets of drug therapy'</a> below.)</p><p></p><p class="headingAnchor" id="H2904558025"><span class="h2">Stem cells as cell replacement therapy</span><span class="headingEndMark"> — </span>Stem cells that have been taken out of the body and modified (autologous) or harvested from another individual (allogeneic) can be used to replace the person's own cells that either carry a pathogenic variant or have been destroyed. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenic variant</strong> – Changes to stem cells causing them to produce abnormal progeny may be due to a heritable/genetic condition such as sickle cell disease or thalassemia or to an acquired condition such as leukemia or a neurodegenerative disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Destruction</strong> – Loss of stem cells may be due to an acquired disorder (autoimmune destruction, radiation exposure) or done therapeutically, such as bone marrow ablation using chemotherapy and radiation prior to hematopoietic stem cell transplantation.</p><p></p><p>The use of stem cells to replace abnormal or missing cells is conceptually compelling, and the identification of stem cells in a number of tissue types offers great promise for expanded clinical applications. There is the additional potential that patient-specific induced pluripotent cells may be a source of virtually any cell type. However, several issues remain to be addressed. (See <a class="local">'Challenges with stem cells as replacement'</a> below.)</p><p class="headingAnchor" id="H744456693"><span class="h3">Somatic stem cell-based replacement therapy</span><span class="headingEndMark"> — </span>The paradigm for stem cells as a means of replacing diseased or injured tissue was first explored in response to the threat of nuclear war after World War II. Research on overcoming the effects of radiation injury led to the first demonstration of stem cells, the existence of which had been hypothesized since the early twentieth century.</p><p>Subsequently, it has been shown that both manipulated and unmanipulated stem cells can have a tremendous role in otherwise potentially fatal conditions. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hematopoietic system</strong> – In 1963, researchers demonstrated that a bone marrow-derived cell could replace all the blood elements and rescue an otherwise lethally irradiated animal by simple infusion of donor cells into the blood [<a href="#rid25">25</a>]. (See  <a class="medical medical_review" href="/d/html/6589.html" rel="external">"Clinical manifestations, evaluation, and diagnosis of acute radiation exposure", section on 'Acute radiation syndrome'</a>.)</p><p></p><p class="bulletIndent1">Over the ensuing decades, hematopoietic stem cell transplantation became a standard means of treating hematologic malignancies as well as certain heritable and acquired bone marrow failure states, including radiation injury and other hematopoietic cell disorders such as thalassemia.</p><p></p><p class="bulletIndent1">Subsequent work has also investigated the use of gene therapy with modified autologous hematopoietic cells to treat disorders such as adrenoleukodystrophy, sickle cell disease, and thalassemia. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin</strong> – In 1975, it was reported that cultured cells from the skin could generate large numbers of cells sufficient to provide an autologous cutaneous barrier in patients with severe burns [<a href="#rid26">26</a>]. </p><p></p><p class="bulletIndent1">In another study in a seven-year-old child with the severe genetic disease junctional epidermolysis bullosa, genetic correction of the disease-causing variant in autologous skin stem cells, followed by transplantation of cultured skin grafts, resulted in regeneration of the skin [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/15453.html" rel="external">"Overview of the management of epidermolysis bullosa", section on 'Experimental therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone grafting</strong> – Mesenchymal stem cells are used for bone grafting in orthopedics [<a href="#rid28">28,29</a>]. (See  <a class="medical medical_review" href="/d/html/134456.html" rel="external">"Basic principles of bone grafts and bone substitutes"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cornea</strong> – Limbal stem cells (from the region between the cornea and the bulbar conjunctiva) are used for corneal generation in ophthalmology practice [<a href="#rid30">30</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other tissues</strong> – The identification of stem cells in other tissue types has led to the preclinical testing of stem cell therapies for other disorders, including those involving muscle and nerve tissue. </p><p></p><p class="bulletIndent1">The potential use of stem cells to restore missing, lost, or damaged tissues plays a central role in the field of regenerative medicine, which seeks to improve organ function by regenerating tissue [<a href="#rid31">31</a>].</p><p></p><p class="headingAnchor" id="H1532536423"><span class="h3">Embryonic stem (ES) cell-based replacement therapy (investigational)</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical studies</strong> – Human ES cells have been successfully differentiated in vitro into multiple cell types with the potential for therapeutic use, including retinal cells, oligodendrocytes, pancreatic cells, cardiomyocytes, motor and dopaminergic neurons, and hematopoietic precursor cells [<a href="#rid32">32</a>]. Unlike somatic stem cells, which can be harvested from the individual and used for autologous transplantation, ES cells used for cell replacement therapy are allogeneic (from another individual).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Retinal disease</strong> – Stem cell-based therapies are under investigation for retinal disease. (See  <a class="medical medical_review" href="/d/html/6911.html" rel="external">"Retinitis pigmentosa: Treatment", section on 'Experimental therapies'</a>.)</p><p></p><p class="bulletIndent2">A 2015 report described use of ES cells to treat 18 patients with retinal disease (dry age-related macular degeneration or Stargardt's macular dystrophy) [<a href="#rid33">33</a>]. This involved direct injection of pure retinal pigment epithelium (RPE) cells into the subretinal space, using 50,000 to 150,000 RPE cells (with &gt;9 percent purity) differentiated from ES cells. Graft survival was demonstrated by an increasing subretinal tissue in most patients; visual acuity improved in the injected eye in 10 of 18 individuals (56 percent). Low-dose <a class="drug drug_general" data-topicid="9971" href="/d/drug information/9971.html" rel="external">tacrolimus</a> and <a class="drug drug_general" data-topicid="9670" href="/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil were used for immunosuppression beginning one week before the procedure and continuing for six weeks, followed by six additional weeks of mycophenolate mofetil only. During a median follow-up of 22 months, there was no evidence of adverse proliferation, rejection, or serious ocular or systemic toxicity. </p><p></p><p class="bulletIndent2">Subsequent small studies have evaluated use of ES cell-derived RPE cells for macular degeneration using various approaches, and the results appear to demonstrate clinical benefit and safety [<a href="#rid34">34-36</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Heart disease</strong> – Stem cell-based therapies are under investigation for heart disease. (See  <a class="medical medical_review" href="/d/html/3478.html" rel="external">"Investigational therapies for management of heart failure", section on 'Stem cell therapy'</a>.)</p><p></p><p class="bulletIndent2">ES-based cellular therapy was reported in a study of six patients with severe ischemic left ventricular dysfunction [<a href="#rid37">37</a>]. Human ES cell-derived cardiovascular progenitor cells embedded in a fibrin patch were epicardially delivered through a coronary artery bypass procedure, and technical feasibility and safety were demonstrated. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Diabetes</strong> – Stem cell-based therapies are under investigation for diabetes [<a href="#rid38">38,39</a>]. (See  <a class="medical medical_review" href="/d/html/1767.html" rel="external">"Pancreas and islet transplantation in diabetes mellitus", section on 'Alternative islet sources'</a>.)</p><p></p><p class="bulletIndent2">Preliminary outcomes were reported in a cohort of 15 patients with type 1 diabetes treated with ES cell-derived pancreatic endoderm cells (PECs) implanted subcutaneously in a macroencapsulation device [<a href="#rid40">40</a>]. Increased markers of pancreatic function were observed including fasting C-peptide levels and mixed meal-stimulated C-peptide secretion, indicative of meal-regulated insulin secretion. Therapy was well tolerated, with no teratoma formation or severe graft-related adverse events under immunosuppressive treatment. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurologic disorders</strong> – Clinical studies are ongoing to evaluate ES cell-based therapies for Parkinson disease, spinal cord injury, and amyotrophic lateral sclerosis [<a href="#rid41">41-43</a>]</p><p></p><p class="bulletIndent1">Additional studies are needed to assess the cell dosage, efficacy, and long-term safety in a larger number of patients. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preclinical studies</strong> – ES cell-derived somatic stem cells have also been evaluated in preclinical animal models of various disorders [<a href="#rid44">44-52</a>].</p><p></p><p class="headingAnchor" id="H950289887"><span class="h3">Induced pluripotent stem (iPS) cell-based therapies (investigational)</span><span class="headingEndMark"> — </span>The recognition that a somatic cell taken from an individual can be induced to become a pluripotent stem cell capable of forming any other cell type in the body provides additional opportunities for regenerative medicine because these methods allow easily accessible autologous cells such as skin fibroblasts or hematopoietic cells to be reprogrammed into other cell types via an iPS cell intermediate. The cells can theoretically be used for tissue regeneration in the same patient  (<a class="graphic graphic_figure graphicRef51751" href="/d/graphic/51751.html" rel="external">figure 4</a>). (See <a class="local">'Induced pluripotent stem (iPS) cells'</a> above.)</p><p>The technology for creating iPS cells from differentiated autologous cells could overcome two important obstacles associated with human ES cells:</p><p class="bulletIndent1"><span class="glyph">●</span>Immune rejection after transplantation</p><p class="bulletIndent1"><span class="glyph">●</span>Ethical concerns regarding the use of human embryos </p><p></p><p>The use of iPS cell-derived cellular replacement products would be particularly powerful in monogenic diseases, where "patient-specific" iPS can be generated, the diseased gene in those cells potentially corrected, and the gene-corrected cells transplanted to restore organ function. The field of gene editing, which facilitates gene correction, is rapidly evolving [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Gene editing'</a>.)</p><p>Investigation is in the early stages:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preclinical studies</strong> – Many of the studies to evaluate iPS cells as a source of cell replacement are being conducted in rodents. Examples of animal models for which iPS cells have been generated and used to differentiate cells that could then be transplanted for therapy include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Parkinson disease [<a href="#rid54">54,55</a>] </p><p class="bulletIndent2"><span class="glyph">•</span>Muscular dystrophy [<a href="#rid56">56</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Spinal cord injury [<a href="#rid57">57</a>]</p><p class="bulletIndent2"><span class="glyph">•</span>Type 1 diabetes </p><p class="bulletIndent2"><span class="glyph">•</span>Sickle cell disease [<a href="#rid58">58</a>]</p><p></p><p class="bulletIndent1">Feasibility in a nonhuman primate model of diabetes was demonstrated by generating pancreatic islets from human iPS cells and transplanting them by intraportal infusion. This strategy restored endogenous insulin secretion and improved glycemic control. Long-term follow-up demonstrated improvement in average hemoglobin A1C values and a reduction in exogenous insulin requirement by 49 percent 15 weeks after transplantation [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1">The approach of using iPS cells to correct a genetic disorder has also been tested using human cells. As examples:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Fanconi anemia (FA)</strong> – A normal version of an abnormal FA gene was introduced into fibroblasts from patients with FA, and the gene-corrected cells were reprogrammed to generate patient-specific iPS cells that could generate blood cell types similar to cells from unaffected individuals [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/d/html/109777.html" rel="external">"Management and prognosis of Fanconi anemia"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Huntington disease (HD)</strong> – The abnormally expanded cytosine-adenine-guanine (CAG) trinucleotide repeat region of the huntingtin gene was corrected to normal length in fibroblasts derived from a patient with HD, and the fibroblasts were reprogrammed to generate iPS cells, which were then differentiated into gamma-aminobutyric acid (GABA)-producing neurons [<a href="#rid61">61</a>]. When transplanted into mice, the neurons were able to populate the basal ganglia and express GABA. In cell culture, the neurons showed normalization of signaling pathways, reduced susceptibility to cell death, and improved mitochondrial function, all of which are thought to be involved in the pathogenesis of HD. (See  <a class="medical medical_review" href="/d/html/6182.html" rel="external">"Huntington disease: Genetics and pathogenesis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Duchenne muscular dystrophy</strong> – Human iPS cell lines derived from individuals with Duchenne muscular dystrophy have undergone gene editing and then were directed to differentiate into skeletal muscle progenitor cells [<a href="#rid56">56</a>]. These cells displayed in vivo myogenic potential upon transplantation into immunodeficient mice and restored dystrophin. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical studies </strong>– Clinical studies using iPS cells to regenerate tissues have been initiated or designed in the areas of Parkinson disease, macular degeneration, retinitis pigmentosa, heart failure, spinal cord injury, cartilage defects, platelet transfusion, graft-versus-host disease (GVHD), and cancer immunotherapy [<a href="#rid41">41,62</a>]. </p><p></p><p class="bulletIndent1">iPS cell-derived retinal pigment epithelium (RPE) cells have been transplanted in a clinical study in a single patient with age-related macular degeneration, from whom autologous fibroblasts were used to generate iPS cells that were then differentiated into RPE and transplanted back to the patient [<a href="#rid63">63</a>]. The graft was well tolerated and visual acuity had not changed one year after the intervention. Before transplantation, the iPS cell-derived cells were screened for acquired mutations. A second patient who was selected for this clinical trial did not receive the transplant after testing revealed DNA alterations in the iPS cell-derived RPE cells. The efficacy and safety of iPS cell-derived transplants, therefore, remains unproven.</p><p></p><p class="headingAnchor" id="H3982200"><span class="h3">Challenges with stem cells as replacement</span><span class="headingEndMark"> — </span>Several complexities must be addressed before widespread application of cell replacement using stem cell-based therapies becomes feasible [<a href="#rid41">41</a>]. These hurdles are not likely to be prohibitive, but each will require considerable effort and attention.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissue integration</strong> – The ability of the transplanted cells to integrate into surrounding tissues to achieve a physiologically beneficial effect is of particular relevance where coordination of complex networks of cells is essential, such as in the heart and brain. Aberrant electrical circuits in these tissues can result in serious adverse events. </p><p></p><p class="bulletIndent1">Although extensive testing is needed, one encouraging observation is that some cells appear to have an inherent capacity to incorporate into existing structures. As an example, in an animal model, human endothelial cells derived from ES cells were able to organize into tubular structures and integrate into the host vasculature when inserted as dispersed cells into a host tissue [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Oncogenesis</strong> – The potential for transplanted cells to form tumors is of particular importance when using pluripotent cells, since these can form teratomas (neoplastic tumors containing cells corresponding to all three embryonic layers) in animal models [<a href="#rid23">23,41,65</a>]. Development of hematologic malignancies following transplantation of modified hematopoietic stem cells is a significant concern that may apply more to some underlying disorders than others. (See  <a class="medical medical_review" href="/d/html/110324.html" rel="external">"Investigational therapies for sickle cell disease", section on 'Concern about myeloid malignancy in allogeneic transplantation'</a> and  <a class="medical medical_review" href="/d/html/5929.html" rel="external">"Hematopoietic stem cell transplantation in sickle cell disease"</a>.)</p><p></p><p class="bulletIndent1">Tumorigenesis could result from several mechanisms [<a href="#rid41">41</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For products derived from pluripotent cells, teratomas or tumors might arise from undifferentiated or immature cells retained in the final differentiated cell product.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Somatic mutations may occur during in vitro culture that lead to tumor formation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For iPS cells, reprogramming factors such as c-Myc, which has oncogenic potential, may remain active [<a href="#rid66">66</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Methods of cell transduction such as retroviruses and lentiviruses have oncogenic potential by virtue of their ability to integrate into the host genome [<a href="#rid67">67</a>]. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Integrating versus nonintegrating vectors'</a>.)</p><p></p><p class="bulletIndent2">This final concern has been mitigated by the introduction of efficient, integration-free methods for cell reprogramming involving the transient expression of reprogramming factors using adenoviruses, plasmids, transposons, Sendai viruses, synthetic mRNAs and recombinant proteins. These developments may mitigate the concerns about insertional mutagenesis, but will not entirely assuage concern for altered growth control of modified cells, particularly those with pluripotency. </p><p></p><p class="bulletIndent1">The differentiation state of transplanted cells will need to be defined with high precision to avoid delivery of residual pluripotent cells that may differentiate aberrantly in vivo. Ruling out the presence of potentially oncogenic genetic alterations in iPS cells and their derivative cells remains critical for use in clinical cell therapies.</p><p></p><p class="bulletIndent1">Evidence also suggests that oncogenesis is not restricted to pluripotent cells. In one case, a child was given cultured fetal brain cells intrathecally and subsequently developed multiple central nervous system tumors of donor origin [<a href="#rid68">68</a>]. The culture process may enable the outgrowth of genetically abnormal cell types that could be of potential danger [<a href="#rid69">69</a>]. The specifics of what types of testing will be required for pluripotent or other cells to assure genetic integrity of transplanted cells is an active area of consideration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differentiation state of the cells</strong> – Generating the proper cell type from pluripotent cells remains a significant challenge for some cell types. Protocols have been devised to create some neural cell types of clear clinical importance [<a href="#rid70">70</a>]. However, for other tissues, such as the blood, the cell types created most closely resemble embryonic blood cells and are not capable of engrafting the bone marrow without further and undesirable genetic manipulation [<a href="#rid71">71</a>].</p><p></p><p class="bulletIndent1">Achieving the right stage of differentiation is another consideration in development of the stem cell-derived cell therapies. It may be most desirable to generate progenitor cells (a type of cell that may be capable of self-renewing for a limited period of time and of creating a narrower range of differentiated progeny), rather than fully mature terminally differentiated cells in some tissues, so that the replaced cells do not quickly senesce and die. Uniformity and consistency of the cell product may be difficult to achieve across different donor sources.</p><p></p><p class="headingAnchor" id="H1281036"><span class="h2">Use of non-engrafting mesenchymal stem cells to modify disease course</span><span class="headingEndMark"> — </span>Beyond use of stem cells for cell replacement, the ability of certain stem cells to alter disease without engrafting has been explored as a means of modifying cellular response to injury or aberrant immune activity. Such non-engrafting stem cells are hypothesized to provide complex signals that may affect disease outcomes without directly replacing injured cells.</p><p>Mesenchymal stem cells were first identified from bone marrow [<a href="#rid72">72,73</a>]. This population of cells is defined primarily by its ability to form colonies in tissue culture, and by the ability of single cells derived from the colonies to differentiate into osteoblasts, adipocytes or chondrocytes in vitro. Identification of these cells and understanding of their in vivo function remains controversial.</p><p>Mesenchymal stem cells have been studied in the following settings of response to injury:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tissue recovery</strong> – The potential for mesenchymal stem cells to form muscle led to exploration of their use in the setting of ischemic injury of the heart. While initial indications suggested that the cells might repopulate cardiac cells, it was subsequently shown that the cells do not engraft [<a href="#rid74">74</a>]. Rather, it is proposed that they provide complex paracrine signals that enhance the ability of cardiac (and other tissues) to respond to ischemic injury [<a href="#rid75">75-77</a>]. This concept remains highly contested, in part because the mechanisms by which stem cells may function in this capacity are not clear. The mesenchymal stem cell populations studied are highly variable and have been variably reported to secrete a number of factors including indoleamine 2, 3-dioxygenase, prostaglandins, interleukin-6, hepatocyte growth factor, inducible nitric oxide synthase, and tumor growth factor (TGF)-beta 1 [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune function</strong> – It has been proposed that the mesenchymal stem cell population is capable of altering immune function and may therefore modulate injury responses as in ischemia, or mitigate the effects of immune-mediated diseases. Mesenchymal stem cells have been tested in clinical trials in humans in settings of GVHD following allogeneic hematopoietic stem cell transplantation. There has been controversy regarding the impact of the cells and the mechanism by which the cells may be acting. (See  <a class="medical medical_review" href="/d/html/3543.html" rel="external">"Treatment of acute graft-versus-host disease", section on 'Mesenchymal stromal cells (MSCs)'</a>.)</p><p></p><p>While this use of stem cell populations as disease-modifying cell platforms is an area of active investigation, the concept should not be considered proven. The prospect that mesenchymal cell populations may have the ability to arrive at sites of injury and provide paracrine signals is an exciting and potentially important application of stem cell biology, but it is not yet a defined therapy.</p><p class="headingAnchor" id="H739456758"><span class="h2">Endogenous stem cells as targets of drug therapy</span><span class="headingEndMark"> — </span>There is emerging recognition that stem cells resident in adult tissues may be targets for pharmacologic interventions with the goal of augmenting the regenerative potential of endogenous stem cells. This approach may avoid concerns related to tissue integration of exogenous or allogeneic cells. (See <a class="local">'Stem cells as cell replacement therapy'</a> above.)</p><p>Growing understanding of the signaling processes that activate stem cells or modify their differentiation increases interest in this approach. Analogous to the use of erythropoietin to modify the activity of red blood cell (RBC) progenitor cells, agents with similar effects on stem cells might facilitate reconstitution of other blood cell types from hematopoietic stem cells or other mature cell types from other tissue stem cells.</p><p>Some studies have identified agents capable of altering stem cell activity after injury to bone or bone marrow [<a href="#rid79">79,80</a>]. As an example, a prostaglandin E2 (PGE2) derivative was identified in a chemical screen to be a potent positive regulator of hematopoietic stem cells in zebrafish, increasing self-renewal capacity and engraftment [<a href="#rid81">81</a>]. In a subsequent study in which patients with hematologic malignancies were treated by hematopoietic stem cell transplantation using umbilical cord blood stem cells, the cells were modified using the PGE2 derivative, and this was associated with accelerated neutrophil recovery and preferential long-term engraftment of the PGE2-treated cells in the recipients [<a href="#rid82">82</a>]. </p><p>PGE2 similarly supports the expansion of human colon stem cells in cell culture, leading to the idea that in vivo manipulation of PGE2 metabolism may modulate stem cells and regeneration of multiple tissue types. A preclinical study in mice demonstrated that treatment with small molecules capable of increasing PGE2 levels promoted tissue regeneration after colon and liver injury [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H3479859346"><span class="h1">RESEARCH APPLICATIONS</span></p><p class="headingAnchor" id="H3982221"><span class="h2">Disease models</span><span class="headingEndMark"> — </span>Stem cells offer the possibility of creating in vitro disease models that may improve molecular understanding of disease and accelerate the development of new therapies. Human cells from individuals with diseases affecting the nervous system, for example, have been extremely difficult to obtain for in vitro analysis. With stem cell approaches, it is possible to generate sufficiently large numbers of cells to study the molecular basis of functional deficits associated with the disease or to be used in the development and testing of new drugs.</p><p>The development of induced pluripotent stem (iPS) cells has generated efforts to create in vitro disease models amenable to genetic and small molecule study. A major goal of such efforts is to identify compounds capable of altering disease progression. These efforts depend upon robust cell culture systems that resemble the in vivo context closely enough to be useful for drug evaluation. Fulfillment of this requirement still needs validation.</p><p>Two early examples depict use of iPS cells to create a disease model for further study of human disease pathogenesis and treatment.</p><p class="bulletIndent1"><span class="glyph">●</span>iPS cell lines were created from patients with familial dysautonomia (FD), a rare fatal sensory autonomic neuropathy caused by a point mutation in the <em>IKBKAP </em>gene, involved in transcriptional elongation [<a href="#rid84">84</a>]. The investigators demonstrated tissue-specific missplicing of <em>IKBKAP</em> in purified FD-iPSC-derived lineages, suggesting a mechanism for disease specificity. Functional studies revealed marked abnormalities in neurogenic differentiation and migration behavior, recapitulating disease characteristics. FD-iPSCs were subsequently used for validating the potency of candidate drugs to reverse aberrant splicing and ameliorate neuronal differentiation and migration. (See  <a class="medical medical_review" href="/d/html/6227.html" rel="external">"Hereditary sensory and autonomic neuropathies", section on 'HSAN3 (Familial dysautonomia)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, iPS cells were generated from skin fibroblasts from a child with spinal muscular atrophy [<a href="#rid85">85</a>]. These cells expanded robustly in culture, maintained the disease genotype, and generated motor neurons that showed selective deficits compared with those derived from the child's unaffected mother.</p><p></p><p>iPS cells have also been used to generate disease models for a wide variety of genetic diseases, including neurologic, hematologic, metabolic, and cardiovascular disorders. These studies have generated novel insights into the molecular mechanisms driving these disorders and platforms for drug screening [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H3599424460"><span class="h2">Cancer therapy</span><span class="headingEndMark"> — </span>An additional application of stem cell biology to disease modeling is in the setting of cancer. If cancer stem cells are present, then treatment must in some way target the cancer stem cells to destroy them and/or prevent growth of tumor cells. (See <a class="local">'Cancer stem cells'</a> above.)</p><p>Studies are investigating whether cancer drugs affect cancer stem cells in the same way they affect differentiated tumor cells and whether specific features of cancer stem cells can be targeted. </p><p class="headingAnchor" id="H3982228"><span class="h1">ETHICAL CONSIDERATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human embryo research</strong> – The first derivation of human embryonic stem (ES) and embryonic germ cells in 1998 sparked enormous interest and controversy. The initial, and still most frequent, techniques used to derive ES cells disrupt the blastocyst from which the cells are derived, raising concern that an early human life form was being destroyed. </p><p></p><p class="bulletIndent1">The source of the blastocyst was generally discarded material from in vitro fertilization (IVF) clinics that was not going to be transferred. Nonetheless, the issue of using the material for research, even if that research was intended to assuage human suffering, was morally unacceptable for many. These controversies led to policy decisions among some nations that precluded ES cell research or, as in the United States, eliminated federal funding support for such research.</p><p></p><p class="bulletIndent1">The advent of reprogramming to generate induced pluripotent stem (iPS) cells has provided an alternative source of pluripotent cells with less ethical concern, since they do not require destruction of embryonic or blastocyst tissue. However, iPS cells have not yet been shown to be fully equivalent to ES cells, and ES cells still represent the best-defined pluripotent cell population. </p><p></p><p class="bulletIndent1">Ethical concerns about gene editing of ES cells are discussed separately. (See  <a class="medical medical_review" href="/d/html/98724.html" rel="external">"Overview of gene therapy, gene editing, and gene silencing", section on 'Ethical concerns with germline genome editing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Defining safety in clinical trials</strong> – A concern regarding the use of any type of stem cells in clinical studies is how to define safety.</p><p></p><p class="bulletIndent1">Safety has been explored in studies using hematopoietic stem cells for transplantation and in dermatology for keratinocyte skin grafts and mesenchymal stem cell transplantation.</p><p></p><p class="bulletIndent1">However, several concerns are unique to pluripotent cells, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Possible aberrant growth in tissues where this could be catastrophic, such as the central nervous system and heart.</p><p class="bulletIndent2"><span class="glyph">•</span>Possible acquisition of genetic variation that disrupts function or is oncogenic. </p><p class="bulletIndent2"><span class="glyph">•</span>Challenges in identifying when the cells have acquired tumorigenic potential.</p><p class="bulletIndent2"><span class="glyph">•</span>Challenges in determining whether the cells can integrate as functional tissue.</p><p></p><p class="bulletIndent1">Clinical experience will be necessary to define some of the risks in stem cell-based therapeutics, and careful design of clinical trials with a range of parameters specific to the field are in process. (See <a class="local">'Challenges with stem cells as replacement'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential for exploitation of patients who are looking for a cure</strong> – Stem cells have enormous potential that is well recognized by the public, and their use is a source of hope for those dealing with otherwise untreatable medical problems. </p><p></p><p class="bulletIndent1">However, the field of stem cell-based therapy is in its infancy, and progress is painstaking. For those desperate to get help, unproven therapies even outside of reputable centers or clinical trials are a highly tempting option. The potential for patient exploitation raises another extremely challenging area. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>There has been a profusion of centers in many parts of the world, often offering treatment without clear definition of what cells would be used, what the source of cells is, and the scope of the clinical experience that is being used to support claims of safety and efficacy, if any. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Services are often offered for cash payment with unclear provisions to monitor the patient following treatment or to respond to adverse events. </p><p></p><p class="bulletIndent1">Patients and their doctors should ask a range of specific questions about such therapies. The International Society for Stem Cell Research (ISSCR) has provided suggested questions and other information that may be of use (<a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.isscr.org%2F&amp;token=g4HO3cPhySa%2BZ%2BXFK1xGQgWZ5yV3xSpWV5dVraBJZEM%3D&amp;TOPIC_ID=14598" target="_blank">www.isscr.org</a>).</p><p></p><p class="headingAnchor" id="H1280948"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and behavior</strong> – Stem cells have the capabilities of self-renewal (indefinite) and differentiation. Stem cells are classified based on the type of differentiated cell they can reproduce. They can divide to create new stem cells or more differentiated cells. Pluripotent stem cells, which include embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, can make all cells of the embryo, including germ cells and cells derived from ectoderm, mesoderm, and endoderm. Somatic stem cells are more limited in repertoire. Some cancers are thought to contain a type of cancer stem cell responsible for tumor persistence and possibly metastasis. (See <a class="local">'Stem cell biology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sources of stem</strong> <strong>cells</strong> – ES cells are typically derived from the preimplantation blastocyst (7 to 10 days postfertilization). iPS cells are created from somatic tissues in the laboratory via reprogramming. Somatic (also called adult or tissue-specific) stem cells typically derive from tissue formed beyond 10 to 14 days postfertilization. Somatic stem cells have been identified in rapidly dividing tissues such as bone marrow, skin, and gastrointestinal tract. Their presence in other tissues such as pancreatic islet cells is unclear. (See <a class="local">'Sources of stem cells for clinical use or research'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical uses</strong> – Stem cells have several clinical applications, although concerns about generating the right stage of differentiation, integrating accurately into target tissues, and promoting oncogenesis remain. Hematopoietic stem cell replacement is a proven therapy for certain hematologic neoplasms, bone marrow failure syndromes, and other heritable conditions such as thalassemia. Burn therapy, bone grafting, and corneal transplant tissues use stem cell-generated tissue. Tissue replacement treatment for other conditions (retinal disease, Parkinson disease, myocardial infarction) is in development. Mesenchymal stem cells may modify diseased tissue without engrafting. Stem cells may be used in the laboratory to study drug efficacy. (See <a class="local">'Clinical applications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ethical considerations</strong> – Ethical concerns include moral objections to destroying blastocysts or embryos for stem cell research, challenges in defining safety in clinical trials, and the potential for "stem cell clinics" to use unproven therapies and exploit patients who lack other treatment options for serious conditions. (See <a class="local">'Ethical considerations'</a> above.)</p><p></p><p class="headingAnchor" id="H205303679"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David T Scadden, MD, and Benjamin A Raby, MD, MPH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006; 441:1068.</a></li><li><a class="nounderline abstract_t">Tajbakhsh S, Rocheteau P, Le Roux I. Asymmetric cell divisions and asymmetric cell fates. Annu Rev Cell Dev Biol 2009; 25:671.</a></li><li><a class="nounderline abstract_t">Blanpain C, Fuchs E. Epidermal stem cells of the skin. Annu Rev Cell Dev Biol 2006; 22:339.</a></li><li><a class="nounderline abstract_t">Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645.</a></li><li><a class="nounderline abstract_t">Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100:3983.</a></li><li><a class="nounderline abstract_t">O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445:106.</a></li><li><a class="nounderline abstract_t">Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311.</a></li><li><a class="nounderline abstract_t">Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1:313.</a></li><li><a class="nounderline abstract_t">Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104:973.</a></li><li><a class="nounderline abstract_t">Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells. Nature 2004; 432:396.</a></li><li><a class="nounderline abstract_t">Lovell-Badge R, Anthony E, Barker RA, et al. ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. Stem Cell Reports 2021; 16:1398.</a></li><li><a class="nounderline abstract_t">Gong JK. Endosteal marrow: a rich source of hematopoietic stem cells. Science 1978; 199:1443.</a></li><li><a class="nounderline abstract_t">Tumbar T, Guasch G, Greco V, et al. Defining the epithelial stem cell niche in skin. Science 2004; 303:359.</a></li><li><a class="nounderline abstract_t">Barker N, van Es JH, Kuipers J, et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007; 449:1003.</a></li><li><a class="nounderline abstract_t">Montarras D, Morgan J, Collins C, et al. Direct isolation of satellite cells for skeletal muscle regeneration. Science 2005; 309:2064.</a></li><li><a class="nounderline abstract_t">Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992; 255:1707.</a></li><li><a class="nounderline abstract_t">Alexander MS, Rozkalne A, Colletta A, et al. CD82 Is a Marker for Prospective Isolation of Human Muscle Satellite Cells and Is Linked to Muscular Dystrophies. Cell Stem Cell 2016; 19:800.</a></li><li><a class="nounderline abstract_t">Garcia SM, Tamaki S, Lee S, et al. High-Yield Purification, Preservation, and Serial Transplantation of Human Satellite Cells. Stem Cell Reports 2018; 10:1160.</a></li><li><a class="nounderline abstract_t">Alvarez Fallas ME, Pedraza-Arevalo S, Cujba AM, et al. Stem/progenitor cells in normal physiology and disease of the pancreas. Mol Cell Endocrinol 2021; 538:111459.</a></li><li><a class="nounderline abstract_t">Kerper N, Ashe S, Hebrok M. Pancreatic β-Cell Development and Regeneration. Cold Spring Harb Perspect Biol 2022; 14.</a></li><li><a class="nounderline abstract_t">Kajstura J, Rota M, Hall SR, et al. Evidence for human lung stem cells. N Engl J Med 2011; 364:1795.</a></li><li><a class="nounderline abstract_t">Drazen JM. Retraction: Kajstura J et al. Evidence for Human Lung Stem Cells. N Engl J Med 2011;364:1795-806. N Engl J Med 2018; 379:1870.</a></li><li><a class="nounderline abstract_t">Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006; 126:663.</a></li><li><a class="nounderline abstract_t">Hou P, Li Y, Zhang X, et al. Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds. Science 2013; 341:651.</a></li><li><a class="nounderline abstract_t">BECKER AJ, McCULLOCH EA, TILL JE. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. Nature 1963; 197:452.</a></li><li><a class="nounderline abstract_t">Rheinwald JG, Green H. Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratoma. Cell 1975; 6:317.</a></li><li><a class="nounderline abstract_t">Hirsch T, Rothoeft T, Teig N, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 2017; 551:327.</a></li><li><a class="nounderline abstract_t">Darveau SC, Leary OP, Persad-Paisley EM, et al. Existing clinical evidence on the use of cellular bone matrix grafts in spinal fusion: updated systematic review of the literature. Neurosurg Focus 2021; 50:E12.</a></li><li><a class="nounderline abstract_t">Khan S, Peracha A, Abro AA, et al. Clinical studies investigating the role of mesenchymal stem cells in healing of fracture non-unions: a systematic review. J Pak Med Assoc 2023; 73(Suppl 1):S26.</a></li><li><a class="nounderline abstract_t">Rama P, Matuska S, Paganoni G, et al. Limbal stem-cell therapy and long-term corneal regeneration. N Engl J Med 2010; 363:147.</a></li><li><a class="nounderline abstract_t">Terzic A, Nelson TJ. Regenerative medicine primer. Mayo Clin Proc 2013; 88:766.</a></li><li><a class="nounderline abstract_t">Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell 2008; 132:661.</a></li><li><a class="nounderline abstract_t">Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2015; 385:509.</a></li><li><a class="nounderline abstract_t">Mehat MS, Sundaram V, Ripamonti C, et al. Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration. Ophthalmology 2018; 125:1765.</a></li><li><a class="nounderline abstract_t">da Cruz L, Fynes K, Georgiadis O, et al. Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration. Nat Biotechnol 2018; 36:328.</a></li><li><a class="nounderline abstract_t">Stern JH, Tian Y, Funderburgh J, et al. Regenerating Eye Tissues to Preserve and Restore Vision. Cell Stem Cell 2018; 22:834.</a></li><li><a class="nounderline abstract_t">Menasché P, Vanneaux V, Hagège A, et al. Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction. J Am Coll Cardiol 2018; 71:429.</a></li><li><a class="nounderline abstract_t">Butler PC, Gale EA. Reversing type 1 diabetes with stem cell-derived islets: a step closer to the dream? J Clin Invest 2022; 132.</a></li><li><a class="nounderline abstract_t">Vantyghem MC, de Koning EJP, Pattou F, Rickels MR. Advances in β-cell replacement therapy for the treatment of type 1 diabetes. Lancet 2019; 394:1274.</a></li><li><a class="nounderline abstract_t">Ramzy A, Thompson DM, Ward-Hartstonge KA, et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes. Cell Stem Cell 2021; 28:2047.</a></li><li><a class="nounderline abstract_t">Yamanaka S. Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Cell Stem Cell 2020; 27:523.</a></li><li><a class="nounderline abstract_t">Pendse S, Vaidya A, Kale V. Clinical applications of pluripotent stem cells and their derivatives: current status and future perspectives. Regen Med 2022; 17:677.</a></li><li><a class="nounderline abstract_t">Blau HM, Daley GQ. Stem Cells in the Treatment of Disease. N Engl J Med 2019; 380:1748.</a></li><li><a class="nounderline abstract_t">Lamba DA, Gust J, Reh TA. Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice. Cell Stem Cell 2009; 4:73.</a></li><li><a class="nounderline abstract_t">Gonzalez-Cordero A, West EL, Pearson RA, et al. Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. Nat Biotechnol 2013; 31:741.</a></li><li><a class="nounderline abstract_t">Kim JH, Auerbach JM, Rodríguez-Gómez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002; 418:50.</a></li><li><a class="nounderline abstract_t">Yang D, Zhang ZJ, Oldenburg M, et al. Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats. Stem Cells 2008; 26:55.</a></li><li><a class="nounderline abstract_t">Ganat YM, Calder EL, Kriks S, et al. Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment. J Clin Invest 2012; 122:2928.</a></li><li><a class="nounderline abstract_t">Ma L, Hu B, Liu Y, et al. Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice. Cell Stem Cell 2012; 10:455.</a></li><li><a class="nounderline abstract_t">Keirstead HS, Nistor G, Bernal G, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci 2005; 25:4694.</a></li><li><a class="nounderline abstract_t">Fernandes S, Chong JJH, Paige SL, et al. Comparison of Human Embryonic Stem Cell-Derived Cardiomyocytes,  Cardiovascular Progenitors, and Bone Marrow Mononuclear Cells for  Cardiac Repair. Stem Cell Reports 2015; 5:753.</a></li><li><a class="nounderline abstract_t">Vegas AJ, Veiseh O, Gürtler M, et al. Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice. Nat Med 2016; 22:306.</a></li><li><a class="nounderline abstract_t">Paolini Sguazzi G, Muto V, Tartaglia M, et al. Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases. Int J Mol Sci 2021; 22.</a></li><li><a class="nounderline abstract_t">Kikuchi T, Morizane A, Doi D, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model. Nature 2017; 548:592.</a></li><li><a class="nounderline abstract_t">Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A 2008; 105:5856.</a></li><li><a class="nounderline abstract_t">Hicks MR, Hiserodt J, Paras K, et al. ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 2018; 20:46.</a></li><li><a class="nounderline abstract_t">Tsuji O, Miura K, Okada Y, et al. Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci U S A 2010; 107:12704.</a></li><li><a class="nounderline abstract_t">Hanna J, Wernig M, Markoulaki S, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007; 318:1920.</a></li><li><a class="nounderline abstract_t">Du Y, Liang Z, Wang S, et al. Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates. Nat Med 2022; 28:272.</a></li><li><a class="nounderline abstract_t">Raya A, Rodríguez-Pizà I, Guenechea G, et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 2009; 460:53.</a></li><li><a class="nounderline abstract_t">An MC, Zhang N, Scott G, et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012; 11:253.</a></li><li><a class="nounderline abstract_t">Kim JY, Nam Y, Rim YA, Ju JH. Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells. Stem Cell Rev Rep 2022; 18:142.</a></li><li><a class="nounderline abstract_t">Mandai M, Watanabe A, Kurimoto Y, et al. Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration. N Engl J Med 2017; 376:1038.</a></li><li><a class="nounderline abstract_t">Wang ZZ, Au P, Chen T, et al. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol 2007; 25:317.</a></li><li><a class="nounderline abstract_t">Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science 1998; 282:1145.</a></li><li><a class="nounderline abstract_t">Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007; 448:313.</a></li><li><a class="nounderline abstract_t">Takahashi K, Yamanaka S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat Rev Mol Cell Biol 2016; 17:183.</a></li><li><a class="nounderline abstract_t">Amariglio N, Hirshberg A, Scheithauer BW, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med 2009; 6:e1000029.</a></li><li><a class="nounderline abstract_t">Merkle FT, Ghosh S, Kamitaki N, et al. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations. Nature 2017; 545:229.</a></li><li><a class="nounderline abstract_t">Dimos JT, Rodolfa KT, Niakan KK, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321:1218.</a></li><li><a class="nounderline abstract_t">Kyba M, Perlingeiro RC, Daley GQ. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell 2002; 109:29.</a></li><li><a class="nounderline abstract_t">Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6:230.</a></li><li><a class="nounderline abstract_t">Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284:143.</a></li><li><a class="nounderline abstract_t">Iso Y, Spees JL, Serrano C, et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007; 354:700.</a></li><li><a class="nounderline abstract_t">Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8:726.</a></li><li><a class="nounderline abstract_t">Burt RK, Loh Y, Pearce W, et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA 2008; 299:925.</a></li><li><a class="nounderline abstract_t">Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 2012; 10:244.</a></li><li><a class="nounderline abstract_t">Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views. Stem Cells 2007; 25:2896.</a></li><li><a class="nounderline abstract_t">Adams GB, Martin RP, Alley IR, et al. Therapeutic targeting of a stem cell niche. Nat Biotechnol 2007; 25:238.</a></li><li><a class="nounderline abstract_t">Mukherjee S, Raje N, Schoonmaker JA, et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118:491.</a></li><li><a class="nounderline abstract_t">North TE, Goessling W, Walkley CR, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007; 447:1007.</a></li><li><a class="nounderline abstract_t">Cutler C, Multani P, Robbins D, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013; 122:3074.</a></li><li><a class="nounderline abstract_t">Zhang Y, Desai A, Yang SY, et al. TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science 2015; 348:aaa2340.</a></li><li><a class="nounderline abstract_t">Lee G, Papapetrou EP, Kim H, et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009; 461:402.</a></li><li><a class="nounderline abstract_t">Ebert AD, Yu J, Rose FF Jr, et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009; 457:277.</a></li><li><a class="nounderline abstract_t">Shi Y, Inoue H, Wu JC, Yamanaka S. Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov 2017; 16:115.</a></li></ol></div><div id="topicVersionRevision">Topic 14598 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16810241" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Asymmetric and symmetric stem-cell divisions in development and cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19575640" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Asymmetric cell divisions and asymmetric cell fates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16824012" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epidermal stem cells of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7509044" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A cell initiating human acute myeloid leukaemia after transplantation into SCID mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12629218" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prospective identification of tumorigenic breast cancer cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17122772" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519691" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Identification and characterization of ovarian cancer-initiating cells from primary human tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18371365" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17210912" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15549107" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Identification of human brain tumour initiating cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34048692" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/75570" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Endosteal marrow: a rich source of hematopoietic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671312" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Defining the epithelial stem cell niche in skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934449" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Identification of stem cells in small intestine and colon by marker gene Lgr5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16141372" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Direct isolation of satellite cells for skeletal muscle regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1553558" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27641304" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : CD82 Is a Marker for Prospective Isolation of Human Muscle Satellite Cells and Is Linked to Muscular Dystrophies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29478895" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : High-Yield Purification, Preservation, and Serial Transplantation of Human Satellite Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34543699" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Stem/progenitor cells in normal physiology and disease of the pancreas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34580120" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Pancreaticβ-Cell Development and Regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21561345" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evidence for human lung stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30332555" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Retraction: Kajstura J et al. Evidence for Human Lung Stem Cells. N Engl J Med 2011;364:1795-806.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16904174" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23868920" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pluripotent stem cells induced from mouse somatic cells by small-molecule compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13970094" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1052770" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29144448" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Regeneration of the entire human epidermis using transgenic stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34062506" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Existing clinical evidence on the use of cellular bone matrix grafts in spinal fusion: updated systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36788388" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Clinical studies investigating the role of mesenchymal stem cells in healing of fracture non-unions: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20573916" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Limbal stem-cell therapy and long-term corneal regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23809322" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Regenerative medicine primer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18295582" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25458728" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29884405" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29553577" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Phase 1 clinical study of an embryonic stem cell-derived retinal pigment epithelium patch in age-related macular degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29859174" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Regenerating Eye Tissues to Preserve and Restore Vision.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29389360" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35104802" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Reversing type 1 diabetes with stem cell-derived islets: a step closer to the dream?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31533905" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Advances inβ-cell replacement therapy for the treatment of type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34861146" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide in patients with type 1 diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33007237" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35703035" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical applications of pluripotent stem cells and their derivatives: current status and future perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31042827" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Stem Cells in the Treatment of Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19128794" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Transplantation of human embryonic stem cell-derived photoreceptors restores some visual function in Crx-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23873086" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12077607" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17951220" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Human embryonic stem cell-derived dopaminergic neurons reverse functional deficit in parkinsonian rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22751106" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Identification of embryonic stem cell-derived midbrain dopaminergic neurons for engraftment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22424902" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Human embryonic stem cell-derived GABA neurons correct locomotion deficits in quinolinic acid-lesioned mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15888645" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26607951" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparison of Human Embryonic Stem Cell-Derived Cardiomyocytes,  Cardiovascular Progenitors, and Bone Marrow Mononuclear Cells for  Cardiac Repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26808346" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Long-term glycemic control using polymer-encapsulated human stem cell-derived beta cells in immune-competent mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34948465" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Induced Pluripotent Stem Cells (iPSCs) and Gene Therapy: A New Era for the Treatment of Neurological Diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28858313" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Human iPS cell-derived dopaminergic neurons function in a primate Parkinson's disease model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18391196" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29255171" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20615974" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Therapeutic potential of appropriately evaluated safe-induced pluripotent stem cells for spinal cord injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18063756" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35115708" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19483674" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22748967" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34532844" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28296613" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Autologous Induced Stem-Cell-Derived Retinal Cells for Macular Degeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17322871" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9804556" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Embryonic stem cell lines derived from human blastocysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17554338" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Generation of germline-competent induced pluripotent stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26883003" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A decade of transcription factor-mediated reprogramming to pluripotency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19226183" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28445466" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18669821" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11955444" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5654088" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10102814" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Multilineage potential of adult human mesenchymal stem cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17257581" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19172693" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Mesenchymal stem cells in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18314435" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22385653" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901396" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17237769" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Therapeutic targeting of a stem cell niche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18219387" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17581586" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23996087" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26068857" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : TISSUE REGENERATION. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19693009" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19098894" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Induced pluripotent stem cells from a spinal muscular atrophy patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27980341" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Induced pluripotent stem cell technology: a decade of progress.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
